REG - Avacta Group PLC - Result of AGM

AvactaAnnouncement

Yesterday 17:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250702:nRSB4867Pa&default-theme=true

RNS Number : 4867P  Avacta Group PLC  02 July 2025

 

Avacta Group plc

 

("Avacta" or the "Group" or the "Company")

Result of AGM

LONDON and PHILADELPHIA - July, 2 2025 - Avacta Group plc (AIM: AVCT), a life
sciences company developing innovative, targeted oncology drugs, today
announces that at the Annual General Meeting (AGM) held this morning, all
resolutions were duly passed by shareholders (with the exception of Resolution
3 which was not put to the meeting).

The results of the voting at the AGM are outlined in the table below and the
presentation materials are available on the Company's website here
(https://avacta.com/investors/investor-resources/) .

             For                 Against              Withheld
 Resolution  Votes       %       Votes        %       Votes
 1           69,286,714  99.84%  111,935      0.16%   2,231,336
 2           52,723,506  77.25%  15,527,142   22.75%  3,379,337
 3           See above   -       See above    -       See above
 4           70,378,158  99.32%  482,896      0.68%   768,931
 5           68,687,888  98.79%  843,416      1.21%   2,098,681
 6           68,241,916  97.50%  1,747,126    2.50%   1,640,943
 7           70,242,593  99.58%  293,323      0.42%   1,094,069
 8           61,988,039  90.99%  6,139,673    9.01%   3,502,273
 9           64,805,029  98.71%  850,095      1.29%   5,974,861
 10          65,957,356  97.83%  1,462,237    2.17%   4,210,392
 11          64,414,344  96.66%  2,229,203    3.34%   4,986,438
 12          64,418,047  96.71%  2,189,948    3.29%   5,021,990
 13          67,217,793  99.14%  580,188      0.86%   3,832,004

Although all the resolutions were passed, the Board of Avacta notes that more
than 20% of votes were cast against Resolution 2. The Board will continue to
engage with shareholders in the periods ahead and remains committed to open
and constructive dialogue in order to understand shareholders' views. To this
end, shareholders who voted against resolution 2 can email any views to
avacta@icrhealthcare.com (mailto:avacta@icrhealthcare.com) .

 

-Ends -

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                           https://avacta.com/ (https://avacta.com/)

 Michael Vinegrad,

 Group Communications Director

 Peel Hunt (Nomad and Joint Broker)                          www.peelhunt.com (http://www.peelhunt.com)

 James Steel / Chris Golden

 Panmure Liberum (Joint Broker)                              www.panmureliberum.com (http://www.panmureliberum.com)

 Emma Earl / Will Goode / Mark Rogers

 Zeus (Joint Broker)                                        www.zeuscapital.co.uk (http://www.zeuscapital.co.uk)

 James Hornigold / George Duxberry

 Dominic King

 ICR Healthcare                                             avacta@icrhealthcare.com (mailto:avacta@icrhealthcare.com)

 Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert

 Investor Contact                                           renee@thrustsc.com (mailto:renee@thrustsc.com)

 Renee Leck

 THRUST Strategic Communications

 Media Contact                                              Carly@carlyscadutoconsulting.com (mailto:Carly@carlyscadutoconsulting.com)

 Carly Scaduto

 Carly Scaduto Consulting

 

 

About Avacta - https://avacta.com/ (https://avacta.com/)

Avacta Therapeutics is a clinical-stage life sciences company expanding the
reach of highly potent cancer therapies with the pre|CISION(®) platform.
pre|CISION(®) is a proprietary warhead delivery system based on a
tumor-specific protease (fibroblast activation protein or FAP) that is
designed to concentrate highly potent warheads in the tumor microenvironment
while sparing normal tissues. Our innovative pipeline consists of
pre|CISION(®) peptide drug conjugates (PDC) or Affimer(®) drug conjugates
(AffDC) that leverage the tumor-specific release mechanism, providing unique
benefits over traditional antibody drug conjugates.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGEASXAESASEFA